The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

Gestational Diabetes Mellitus Clinical Trial

Official title:

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01795248
• Other study ID #: GDM-TREAT
• Secondary ID: 2012-001371-37
• Status: Completed
• Phase: Phase 4
• Start date: July 2012
• Est. completion date: September 2020

Study information

• Verified date: November 2020
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: September 2020
• Est. primary completion date: September 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for women with previous GDM:

• Informed oral and written consent
• Previous diagnosis of GDM according to current Danish guidelines (mainly PG concentrationa t 120 min after 75 g OGTT = 9.0 mM) during pregnancy within the last 5 years
• Age >18 years
• 25 kg/m2 < BMI < 45 kg/m2
• NGT, IFG and or IGT
• Safe contraception and negative pregnancy test

Exclusion Criteria for women with previous GDM:

• Patients with diabetes
• HbA1c =6.5%
• Patients with previous pancreatitis or previous neoplasia
• Pregnant or breast feeding women
• Anaemia (haemoglobin <7 mM)
• Women planning to become pregnant within the next 5 years
• Women using other contraception than intrauterine device (IUD) or oral contraceptives. Women who do not use safe contraception will be offered application of an IUD.
• Women treated with statins, corticosteroids or other hormone therapy (except estrogens and gestagens)
• Ongoing abuse of alcohol or narcotics
• Impaired hepatic function (liver transaminases >3 times upper normal limit)
• Impaired renal function (se-creatinine >120 µM and/or albuminuria)
• Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)
• Any condition that the investigator feels would interfere with trial participation
• Receiving any investigational drug within the last 3 months

Inclusion criteria for women without previous GDM:

• Informed oral and written consent
• Age >18 years
• 25 kg/m2 < BMI < 45 kg/m2
• NGT
• Safe contraception and negative pregnancy test
• Pregnancy within the last ten years without GDM

Exclusion Criteria for women without previous GDM :

• Pregnant or breast feeding women
• Anaemia (haemoglobin <7 mM)

Inclusion Criteria for women without previous GDM and without NAFLD:

• Informed oral and written consent
• Age >18 years
• 25 kg/m2 < BMI < 45 kg/m2
• NGT
• At least one pregnancy witin the last ten years without GDM

Exclusion Criteria for women without previous GDM and without NAFLD:

• Pregnant or breast feeding women
• Anaemia (haemoglobin <7 mM)
• Steatosis as assessed by ultrasound scanning
• Recieving any investigational drug within the last 3 months
• Any condition that the investigator feels would interfere with the trial participation

Inclusion Criteria for women with biopsi-verified NAFLD:

• Informed oral and written consent
• Women with known NAFLD or NASH
• Age >18 years
• 25 kg/m2 < BMI < 45 kg/m2
• NGT
• At least one prior pregnancy

Exclusion Criteria for women with biopsi-verified NAFLD:

• women with established cirrhosis
• Pregnant or breast feedning women
• Anaemia (haemoglobin <7 mM)
• Women treated with statins, corticosteroids or other hormone therapy ( except oestrogens and gestagens)
• Ongoing abuse of alcohol or narcotics
• Impaired renal function (se-creatinine > 120 µM and/or albuminuria)
• Uncontrolled hypertension (systolic blood pressure > 180 mmHg, diastolic blood presure > 100 mmHg)
• Any condition that the investigator feels would interfere with trial participation

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes, Gestational
• Gestational Diabetes Mellitus

Intervention

Drug:
• Liraglutide
1.8 mg liraglutide
• Placebo
Liraglutide without the GLP-1 analogue

Locations

Country	Name	City	State
Denmark	Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen	Hellerup

Sponsors (9)

Lead Sponsor	Collaborator
Tina Vilsboll	Aarhus University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, Hvidovre University Hospital, Novo Nordisk A/S, Rigshospitalet, Denmark, The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

References & Publications (18)

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322. — View Citation

Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984. — View Citation

Bian X, Gao P, Xiong X, Xu H, Qian M, Liu S. Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus. Chin Med J (Engl). 2000 Aug;113(8):759-62. — View Citation

Damm P, Vestergaard H, Kühl C, Pedersen O. Impaired insulin-stimulated nonoxidative glucose metabolism in glucose-tolerant women with previous gestational diabetes. Am J Obstet Gynecol. 1996 Feb;174(2):722-9. — View Citation

Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. — View Citation

Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. — View Citation

Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011 Mar;54(3):641-7. doi: 10.1007/s00125-010-2009-0. Epub 2010 Dec 12. — View Citation

Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998 Aug;19(4):491-503. Review. — View Citation

Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med. 2002 May;19(5):351-8. Review. — View Citation

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. Review. — View Citation

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602. — View Citation

Jensen DM, Mølsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol. 2003 Nov;189(5):1383-8. — View Citation

Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P, Locht H, Pedersen O, Damm P. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004 May;27(5):1194-9. — View Citation

Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998 Aug;21 Suppl 2:B161-7. — View Citation

Porte D Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci. 1999 Nov 18;892:73-83. Review. — View Citation

Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004 Mar;47(3):357-366. doi: 10.1007/s00125-004-1342-6. Epub 2004 Feb 13. Review. — View Citation

Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull. 2004 Nov;51(4):364-70. — View Citation

Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010 Oct;59(10):2625-30. doi: 10.2337/db10-0521. Epub 2010 Aug 3. — View Citation

* Note: There are 18 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in glycated hemoglobin	Changes in glycated hemoglobin (HbA1c). From normoglycaemic to prediabetic or type 2 diabetic and from prediabetic to type 2 diabetic or normoglycaemic.	From baseline to 52 wks and 260 wks
Other	Changes in anthropometric measurements	Changes in body mass index (BMI)(kg/m2), absolute body weight (kg), and waist:hip ratio	from baseline to 52 and 260 wks
Other	Changes in beta cell secretory responses	changes in area under the curve during OGTT and isoglycemic intravenous glucose infusion (IIGI), the homeostatic model assessment (HOMA) and pro-insulin ratio	from baseline to 52, 53, 260, and 261 wks
Other	Changes in insulin sensitivity	assessed by HOMA-IR and Matsuda insulin sensitivity index	from baseline to 52, 53, 260, and 261 wks
Other	Changes in incretin hormone secretion	measured as fasting plasma concentrations and plasma responses of GLP-1, GLP2, and GIP and plasma glucagon during OGTT	baseline to 52, 53, 260, and 261 wks
Other	Changes in incretin effect	insulin and c-peptide responses after OGTT vs. IIGI	baseline to 52, 53, 260, and 261 wks
Other	Changes in presence of non-alcoholic fatty liver disease (NAFLD)	gamma-glutamyltranferase (GGT), intra-heptic fat, FGF-21, whole body and visceral fat mass/fat-free mass, circulating lipids, ultrasound scan and fibroscan	baseline to 52 and 260 wks
Other	Changes in cardio-metabolic risk measures	pro-collagen 3, GGT, Intra-hepatic fat, whole body and visceral fat mass/fat-free mass, circulating lipids and cardiovascular biomarkers (highly sensitive c-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), tumor necrosis factor-alpha (TNF-alpha), adiponectin and plasminogen activator inhibior-1 (PAI-1))	baseline to 52 and 260 wks
Other	Changes in gut microbiota	optional to the main protocol	baseline to 52 and 260 wks
Other	Changes in subjective appetite	visual analogue scale (VAS)	baseline to 52, 53, 260, and 261 wks
Other	Number of participants with treatment-related adverse events (Safety and tolerability)	as assessed by validated questionnaires	baseline to 52 and 260 wks
Other	Change in Quality of life	Assessed by validated questionnaires (SF-36)	Baseline to 52 and 260 wks
Other	Evaluation of alcohol consumption	By validated questionnaires	baseline to 52 and 260 wks
Other	Evaluation of microalbuminuria	Predicitve value of biomarkers for detection of microalbuminuria	baseline to 52 to 260 wks
Other	Evaluation of blindedness of participants and investigators	questionnaire and the end of the blinded trial	baseline to 52 wks
Other	Changes in bonemarkers		baseline to 52 and 260 wks
Primary	Change in glucose tolerance	Changes in glucose is measured by area under the curve for the plasma glucose excursion following a 4-hour 75 g oral glucose tolerance test (OGTT)	from baseline to 52 wks, 53 wks, 260 wks, and 261 wks
Secondary	Deterioration in glycaemic status	Percentage of subjects in each treatment arm with normal glucose tolerance (NGT) at inclusion who develop impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) or type 2 diabetes; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop type 2 diabetes	from baseline to 52 wks, 53, wks, 260 wks, and 261 wks

External Links

•   Main website for the University Hospital Gentofte